Inebilizumab-cdon reduces neuromyelitis optica spectrum disorder attack severity
February 21st 2022According to data presented by Horizon Therapeutics at the North American Neuro-Ophthalmology Society annual meeting in Austin, Texas, Upliznq treatment is linked to fewer severe attacks and reduced levels of key disease-related biomarkers versus placebo.
Read More
Kriya Therapeutics company recently took the wraps off an exclusive agreement with the Medical University of South Carolina (MUSC) Foundation for Research Development to license next generation complement-targeted gene therapies for the treatment of geographic atrophy and other ocular diseases.
Read More
FDA grants IND clearance for AffaMed's AM712 to treat retinal vascular diseases
February 19th 2022AM712 is a novel bispecific biologic molecule specifically designed for ocular use. In pre-clinical studies, it demonstrated efficacy, ocular pharmacokinetics, and the desired safety profile supporting clinical exploration.
Read More
Alzheimer disease: The retina may predict cognitive changes in middle age
February 17th 2022Researchers know that parts of the retina are considered as biomarkers for Alzheimer disease, but the team from Otago’s Dunedin Multidisciplinary Health and Development Research Unit in New Zealand have been investigating the retina’s potential to indicate cognitive change earlier in life.
Read More
USC launches Center for Neuronal Longevity to address gaps in neurodegenerative disease treatment
February 3rd 2022Center for Neuronal Longevity brings together the research power of the Keck School of Medicine of USC, USC Viterbi School of Engineering, and the USC School of Pharmacy to tackle neurodegenerative diseases of the eye and brain.
Read More
Video game software created for AMD research, uses OCT imaging in gameplay
January 29th 2022A partnership that includes BALANCED Media|Technology, the Retina Foundation of the Southwest and Southern Methodist University is seeking a patent for machine learning software for OCT images aids in identity progression and treatment options.
Read More
FDA grants clearance to IND for MCO-010 gene therapy in Stargardt patients
January 28th 2022Nanoscope Therapeutics has received IND clearance from the FDA to begin a Phase 2 trial of its Multi-Characteristic Opsin ambient-light activatable optogenetic monotherapy to restore vision in Stargardt patients.
Read More
Faricimab improved and maintained vision for patients with wet AMD, DME
January 26th 2022Across four studies, about half of eligible faricimab patients were able to go 4 months between treatments, and approximately three-quarters could be treated every 3 months or longer. Two papers published in The Lancet highlight one-year results.
Read More
Smart harness alerts visually impaired people to obstacles while walking
January 23rd 2022According to the company, biped.ai includes a comfortable and lightweight collar fitted with 3D cameras that continuously monitor a 170° field of view for the user detecting, tracking and predicting the trajectories of all surrounding elements a few seconds in advance.
Read More
Difference in retinal age and real age linked to increased death risk
January 21st 2022The difference between retina’s biological age and person’s real age linked to heightened death risk, with a team of Australian investigators finding that evidence suggests the microvasculature in the retina may be a reliable indicator of the overall health of the body’s circulatory system and the brain.
Read More
National Eye Institute grants funding to WVU to study the mechanism of retinal degeneration
January 19th 2022According to researchers, gaining a good understanding of what Musashi proteins do and how to manipulate their function could lead to the development of a universal therapy for blinding diseases.
Read More